Product Description
Mechanisms of Action: IL2 Inhibitor
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: Canada, Korea, Spain, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
GS-US-616-6291 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2025-12-01 |